Journal of Cardiovascular Computed Tomography
Volume 4, Issue 3 , Pages 164-172 , May 2010

Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: Rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study

Received 23 December 2009 ,Accepted 9 March 2010.

References 

  1. World Health Report 2002. Available at: http://www.worldheart.org. 2007. Accessed September 29, 2009.
  2. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–1844
  3. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  4. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508
  5. Nissen SE, Gurley JC, DeMaria AN. Assessment of vascular disease by intravascular ultrasound. Cardiology. 1990;77:398–410
  6. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–2122
  7. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146:483–494
  8. Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002;15:62–67
  9. Akram K, Rinehart S, Voros S. Coronary arterial atherosclerotic plaque imaging by contrast-enhanced computed tomography: fantasy or reality?. J Nucl Cardiol. 2008;15:818–829
  10. Rinehart S, Vazquez G, Qian Z, Voros S. Coronary plaque imaging with multi-slice computed tomographic angiography and intravascular ultrasound: a close look inside and out. J Invasive Cardiol. 2009;21:367–372
  11. Voros S. What are the potential advantages and disadvantages of volumetric CT scanning?. J Cardiovasc Comput Tomogr. 2009;3:67–70
  12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  13. Wang L, Jerosch-Herold M, Jacobs DR, Shahar E, Detrano R, Folsom AR. Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2006;48:1018–1026
  14. Qian Z, Marvasty I, Anderson H, Rinehart S, Voros S. Lesion-specific coronary artery calcium quantification better predicts cardiac events. Proc IEEE Int Symp Biomed Imaging. 2009;237–240
  15. Voros S. Can computed tomography angiography of the coronary arteries characterize atherosclerotic plaque composition? Is the CAT (scan) out of the bag?. JACC Cardiovasc Interv. 2008;1:183–185
  16. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565
  17. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–2300
  18. Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103:515–522

 Conflict of interest: S.V. has received grant support from Merck Schering Plough and is on the Speaker's Bureau. The other authors report no conflicts of interest.

 The AFRICA study is supported by Abbott Pharmaceuticals.

PII: S1934-5925(10)00135-8

doi: 10.1016/j.jcct.2010.03.005

Journal of Cardiovascular Computed Tomography
Volume 4, Issue 3 , Pages 164-172 , May 2010

Article Tools

* Image Usage & Resolution